ストックスクリーナーアプリを入手
3.32
2.79%
0.09
アフターアワーズ：
3.38
0.06
+1.81%
前日終値:
$3.23
開ける：
$3.3
24時間の取引高:
399.74K
Relative Volume:
0.90
時価総額：
$264.95M
収益：
$16.72M
当期純損益:
$-77.80M
株価収益率:
-3.1401
EPS:
-1.0573
ネットキャッシュフロー:
$-43.78M
1週間 パフォーマンス:
-14.43%
1か月 パフォーマンス:
-26.55%
6か月 パフォーマンス:
-39.86%
1年 パフォーマンス:
+144.12%
1日の値動き範囲:
$3.20
$3.44
1週間の範囲:
$3.20
$3.94
52週間の値動き範囲:
$1.16
$6.83
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
3.32 | 264.95M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-17 | 開始されました | JP Morgan | Overweight |
| 2026-05-04 | 開始されました | D. Boral Capital | Buy |
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Citizens reiterates Prelude Therapeutics stock rating on Lilly deal By Investing.com - Investing.com UK
Wainwright targets Prelude Therapeutics stock at USD 8.00 - ad-hoc-news.de
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial - Yahoo Finance
Lilly will supply two drugs for Prelude's planned breast cancer trial. - Stock Titan
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer - GlobeNewswire
Prelude Therapeutics stock gains 2.72 percent as targets stay high - AD HOC NEWS
Prelude Therapeutics stock falls 9.9 percent despite FDA progress - AD HOC NEWS
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to S&P Global BMI Index - marketscreener.com
Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial - AD HOC NEWS
Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum By Investing.com - Investing.com Canada
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial - MyChesCo
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Four executives will join Prelude’s fireside chat Sept. 16 - Stock Titan
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Prelude Therapeutics Receives FDA Clearance for New Drug Clinical Trial - Intellectia AI
Prelude Therapeutics (PRLD) Gains FDA Nod for Phase 1 Trial in B - GuruFocus
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial - marketscreener.com
Prelude gets FDA clearance for breast cancer drug trial - Investing.com
Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TipRanks
Prelude gets FDA clearance for breast cancer drug trial By Investing.com - Investing.com India
Prelude gets FDA clearance for breast cancer drug trial By Investing.com - Investing.com UK
Prelude Therapeutics Receives FDA Clearance of - GlobeNewswire
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - Yahoo Finance
FDA clears first human study of a breast cancer drug candidate. Prelude expects enrollment in Q4 2026. - Stock Titan
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial - Yahoo Finance
Neuraptive Therapeutics, Inc. Announces Key Org… | UNI India - uniindia.com
Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD) - Seeking Alpha
Prelude Therapeutics (NASDAQ:PRLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 9.3%Time to Buy? - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Prelude Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Prelude Therapeutics Hits New 52-Week High of $5.91, Reflecting Strong Growth - MarketsMojo
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
We're Not Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn - Moomoo
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - webull.com
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports Q2 2026 Earnings Featuring First Revenue and Reduced Losses - Kalkine Media
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics 2Q Loss/Shr 14c >PRLD - Moomoo
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss | PRLD Stock News - Quiver Quantitative
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact - Fierce Biotech
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
Prelude Therapeutics Inc (PRLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 21 '26 |
Buy |
4.44 |
2,815,315 |
12,499,999 |
11,808,945 |
1.35%
大文字化:
|
ボリューム (24 時間):